📰 Solid Tumors Version News
Solid Tumors Version News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors Version. Real-time updates on events, politics, business and more.
December 21, 2023
KIRKLAND, QC, and MISSISSAUGA, ON, Dec. 21, 2023 /CNW/ - Merck , known as MSD outside the United States and Canada, and Eisai announce that KEYTRUDA®, Mercks anti-PD-1 therapy, plus LENVIMA®, an...
June 5, 2023
CHICAGO - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT and lazertinib, a... | June 5, 2023
June 4, 2023
Further analyses from the Phase 1/1b CHRYSALIS-2 study showed patients with osimertinib pre-treated EGFR-mutated lung cancer who have a MET positive...
March 17, 2023
Blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel aloneRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe...
September 10, 2022
Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022 Merck MRK, known as M
September 10, 2022
/PRNewswire/ -- Eisai announced today results from a post-hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301, and...
December 30, 2021
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,...
December 30, 2021
Press release content from PR Newswire. The AP news staff was not involved in its creation.
December 30, 2021
/PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical company dedicated to discovering,...